Nivalis Therapeutics IPO Advisory
Share this IPO Profile:
Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Nivalis Therapeutics, and our comprehensive analysis, click "
Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Nivalis Therapeutics | NVLS - NASDAQ |
$13.00-$15.00 |
$14.00 |
$16.50 | 5.5 million | 6/17/2015 |
Cowen & Co., Stifel |
Co-Manager(s): Baird, H.C. Wainwright & Co. |
Health Care |
Filing(s): Filed 2015-05-13 Terms Added 2015-06-03
|
Nivalis Therapeutics Quote & Chart - Click for current quote -
NVLS
About Nivalis Therapeutics (adapted from Nivalis Therapeutics prospectus):
They are a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for patients with cystic fibrosis, or CF.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "NVLS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2025 IPO Boutique. All Rights Reserved